Anti‐ <scp>IgLON5</scp> Disease: A Systematic Review and Meta‐Analysis
Based on our results, anti-IgLON5 disease should be considered in patients presenting with sleep disorders and additional neurological symptoms that might resemble other diseases but do not fulfill the respective diagnostic criteria. Testing for antibodies in serum has a high sensitivity in this disorder. A limitation of this study is that it was not preregistered.
Authors
- Robert Barket (ORCID: https://orcid.org/0000-0001-6909-6109)
- Harald Hegen
- Anna Heidbreder (ORCID: https://orcid.org/0000-0002-9552-7619)
- Anna Grossauer (ORCID: https://orcid.org/0000-0002-8611-8055)
- Florian Krismer (ORCID: https://orcid.org/0000-0002-4493-5073)
- Beatrice Heim (ORCID: https://orcid.org/0000-0002-6749-3044)
- Klaus Seppi (ORCID: https://orcid.org/0000-0001-6503-1455)
- Nicolas De Cleene
Institutions
- Johannes Kepler University of Linz (AT)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- University of Applied Sciences Kufstein (AT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/ene.70465
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00